Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAML2
REST API REST API
Homo sapiens
MAML2 is differentially expressed in 197 experiments: 90 organism parts: liver, mammary gland, ... (88 more);, 82 disease states: normal, Huntington's disease, ... (80 more);, 83 cell types 333 cell lines 25 compound treatments and 56 other conditions.
Synonyms MAM3, KIAA1819
Orthologs Maml2 (Mus musculus)   MAML2 (Bos taurus)   MAML2 (1 of 2) (Danio rerio)   F1M4B1_RAT (Rattus norvegicus)   Maml2 (Rattus norvegicus)   maml2 (Xenopus laevis)   MAML2 (Canis familiaris)   MAML2 (2 of 2) (Danio rerio)   (Compare orthologs)
Gene Ontology Term nuclear speck, regulation of transcription, DNA-dependent, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, Notch signaling pathway, nucleoplasm, gene expression
UniProt Accession Q8IZL2
InterPro Term Neuroggenic_mastermind-like_N
Search EB-eye ENSG00000184384
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-22541, E-GEOD-6919, E-TABM-130, ... (15 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22560, E-GEOD-14464, E-GEOD-19639, E-GEOD-24147, ... (20 experiments)

Factor Value U/D Experiments
MCF-7
3
 E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
AGS
2
 E-GEOD-15460, E-MTAB-37
DU145
2
 E-GEOD-17482, E-GEOD-20089
HL-60
2
 E-MTAB-37, E-GEOD-24147
HepG2
2
 E-MTAB-37, E-GEOD-7307
LNCaP
2
 E-GEOD-14990, E-GEOD-14464
327 more value(s).


Cell type

studied in E-MEXP-1242, E-TABM-40, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, ... (37 experiments)

Factor Value U/D Experiments
not specified
2
 E-GEOD-18811, E-GEOD-11755
CD14+ CD16- peripheral blood monocyte
1
1
 E-MEXP-1242
activated natural killer cell (supplemented for IL2 for 24 hours)
1
 E-TABM-702
adipose-derived stem cell
1
 E-MEXP-1216
nucleus pulposus
1
 E-MEXP-2488
plasma cell
1
 E-MEXP-2360
77 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-3860, E-GEOD-6872, E-GEOD-15960, E-GEOD-22148, ... (34 experiments)

Factor Value U/D Experiments
myeloma
2
 E-MTAB-372, E-MTAB-37
glioblastoma
2
 E-GEOD-4290, E-MTAB-37
ovarian carcinoma
1
 E-MTAB-37
myeloid leukemia
1
 E-MTAB-37
HPV positive
1
 E-GEOD-3292
neuromuscular pain
1
 E-GEOD-7307
76 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
control - untreated
1
 E-GEOD-7216
unknown
1
 E-GEOD-7307
mannitol
1
 E-GEOD-6400
ZMYM2/FGFR1
1
 E-GEOD-15811
4-hydroxytamoxifen
2
1
 E-MEXP-2241
estradiol
1
 E-GEOD-20081
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
 E-GEOD-19519
tunicamycin
1
 E-GEOD-19519
thapsigargin
1
 E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-20499, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-MEXP-2283

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-19665

Environmental stress
studied in E-GEOD-1643

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-TABM-868, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20504, E-GEOD-9764, ... (9 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-1290, E-MEXP-2069, ... (21 experiments)

Infection
studied in E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1460, E-GEOD-17636, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-1857, E-MEXP-1315, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-13818, E-GEOD-15799

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Processing time: 0.438 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM